HCG Reconstitution Calculator

Yes. HCG is an established prescription gonadotropin used clinically in reproductive and endocrine settings, including ovulation triggering and selected male hypogonadotropic hypogonadism/fertility protocols (systematic review/review). Commercial/clinical use includes both urinary-derived and recombinant preparations, and hCG is also widely used in assisted reproduction protocols studied in humans (RCT/systematic review).

HCG is a luteinizing hormone receptor agonist that mimics the LH surge. In women it is used mainly to trigger final follicular maturation/ovulation in ART and modified natural-cycle protocols; in men it stimulates Leydig-cell testosterone production and is used alone or with FSH/hMG to support spermatogenesis in hypogonadotropic hypogonadism (review/systematic review). HCG is a heterodimeric glycoprotein with substantial glycoform heterogeneity, which partly explains product and assay complexity (mechanistic/analytical).

Yes. Human clinical practice uses HCG for male hypogonadotropic hypogonadism and infertility, often as a first gonadotropin step and then combined with FSH or hMG if sperm production is inadequate (systematic review/review). Established protocols typically use 1,000-2,500 IU SC or IM 2-3 times weekly for testosterone support/fertility induction, escalating duration to months because spermatogenesis is slow (practitioner consensus). If fertility is the goal, treatment is usually measured in months rather than weeks (review/systematic review).

Most commonly as an ovulation trigger in IVF/IUI or modified natural-cycle frozen embryo transfer, and as part of luteal-phase support frameworks after triggering (systematic review/observational review). Practical trigger doses commonly used are 5,000-10,000 IU urinary hCG or 250 mcg recombinant hCG given once pre-ovulation/egg retrieval timing (community protocol). In modified natural-cycle FET, hCG-triggered cycles are common comparators in the literature, though some programmed ovulatory approaches avoid hCG and had similar reproductive outcomes in one propensity-matched study (observational).

Both are used. Human ART data indicate urinary HCG given subcutaneously or intramuscularly is effective, and recombinant and urinary products have shown similar effectiveness for final follicular maturation in donor/ART settings (human trial). In practice, SC is usually easier and preferred for self-administration; IM may still be used depending on product, clinic workflow, or pharmacy supply (practitioner consensus).

That depends on the goal. For ovulation triggering, it is usually a single dose timed to ovulation or egg retrieval (human ART studies/review). For male fertility induction or testicular function support, courses are commonly continued for several months, often with later addition of FSH/hMG if sperm output remains low (review/systematic review). Cycling short 2-4 week “HCG blasts” for fertility is not evidence-based compared with sustained gonadotropin therapy (practitioner consensus).

HCG is a pregnancy hormone, but routine self-directed HCG use during an established pregnancy is not a standard consumer practice. In reproductive medicine, its main role is before implantation/very early cycle timing rather than chronic use through pregnancy, and luteal support literature focuses on when hormonal support can be stopped rather than ongoing HCG administration throughout gestation (review). If pregnancy is confirmed after fertility treatment, follow the treating clinic’s protocol rather than continuing ad hoc injections (practitioner consensus).

Yes. Exogenous HCG can make serum or urine hCG tests positive and can complicate interpretation of pregnancy testing and some tumor-marker workflows (analytical/clinical). HCG assays are also affected by isoform heterogeneity and interference phenomena, so single lab values can occasionally mislead if timing or assay context is ignored (analytical/mechanistic). Practical rule: after a trigger shot, clinicians usually interpret hCG labs relative to timing, not as a standalone “pregnant/not pregnant” result (practitioner consensus).

Usually yes if reconstituted or if the specific product label requires cold storage; dry/powder formulations often travel better than mixed solution (community protocol). Keep the vial/syringes protected from heat and light, carry needles/supplies in original pharmacy packaging, and do not assume all brands have identical storage rules because urinary and recombinant products differ (analytical/product variability).